Most policymakers looking to widen patient access to prescription drugs have zeroed in on price setting as a panacea, as evidenced by the passage of a “negotiation” process in the Inflation Reduction Act last August. The Centers for Medicare & Medicaid Services is currently implementing this process, and our industry has been vocal in our ask that the process put an accurate value on medicines and preserve the access patients need to important treatments.
Continue Reading
